A statewide all-payer claims database would permit more insight into what’s happening with cost and quality of providers, and possibly transform healthcare payment, explained Karen van Caulil, PhD, president and CEO of the Florida Health Care Coalition.
A statewide all-payer claims database (APCD) would permit more insight into what’s happening with cost and quality of providers, and possibly transform healthcare payment, explained Karen van Caulil, PhD, president and CEO of the Florida Health Care Coalition.
Transcript (modified)
What is the benefit of a state having an All-Payer Claims Database?
Yeah, I’d really like it to be an all-payer database, not just claims but also quality data, and so that’s sort of a personal mission of mine to expand it beyond APCD to really an all-payer database. But having that information from all of the different self-funded plans, like we have with our large employers but also those who are fully insured and Medicare and Medicaid, and get it all in one place and look at a market level at what’s happening with providers with cost and quality will be very powerful in this move to transform healthcare payment. Without that information, again, we’re very siloed when we’re individual, and having obviously the legislative mandate to do that would be very, very powerful in a short period of time.
Unfortunately, there’s been a Supreme Court ruling [earlier in 2016] that self-funded plans can’t be required to submit their claims. But in Florida our employers who are self-funded understand the importance of that, and I’m encouraged by their reaction to say “we’ll participate, anyway.”
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
What We’re Reading: HHS' Funding Flat; Mifepristone Safety; Insulin Shortage
March 25th 2024Flat funding for HHS leaves critical health initiatives stagnant; Supreme Court weighs tightening regulations on abortion pill; manufacturing delay sparks access concerns for insulin medication.
Read More
Health Equity and Access Weekly Roundup: March 23, 2024
March 23rd 2024The Center on Health Equity and Access covered disparities in hypertension, diabetic eye health, and hidradenitis suppurativa, along with the proposed legislation banning diversity, equity, and inclusion efforts in Alabama schools and the consequences in sickle cell care from the CDC guideline for opioid prescriptions.
Read More
Mirvetuximab Soravtansine-gynx Granted Full FDA Approval for FRα+ Platinum-Resistant Ovarian Cancer
March 22nd 2024Mirvetuximab soravtansine-gynx (Elahere) received full FDA approval for the treatment of folate receptor alpha–positive (FRα+), platinum-resistant ovarian cancer (PROC) based on findings from the confirmatory phase 3 MIRASOL trial.
Read More